Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Neuroaxonal dystrophy, infantile

Other Names for this Disease
  • INAD
  • Infantile neuroaxonal dystrophy
  • Seitelberger disease
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.


Other Conferences

ORDR-Sponsored Conferences

  • RDCRN 3rd Conference on Clinical Research for Rare Diseases, Tuesday, October 02, 2012
    Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, MD
    Description: Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs. Goals of the conference include: direct instruction of trainees and new investigators in rare disease research methodology; development of a reusable curriculum/syllabus on rare disease research methodology; and stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases.

  • Brain, Blood and Iron: Joint International Symposium on Neuroacanthocytosis and Neurodegeneration with Brain Iron Accumulation, Friday, October 01, 2010 - Saturday, October 02, 2010
    Location: Doubletree Hotel,, Bethesda, Maryland
    Description: The overall objectives of this workshop were to (1) define neuroacanthocytosis (NA) and neurodegeneration with brain iron accumulation (NBIA) research priorities; (2) determine resources that are needed in order to foster research; (3) stimulate interest in research into NA and NBIA among scientists in related fields; (4) generate collaborations between those working in related disciplines, with particular relevance to NA and NBIA; and (5) attract early career investigators to these fields.

  • Third Genome Dynamics in the Neurosciences Conference, Sunday, July 18, 2010 - Thursday, July 22, 2010
    Location: The Hilton Metropole, Brighton, England
    Description: The goal of this meeting was to integrate basic processes of DNA damage signaling and repair and clinical aspects of neurological and neurodegenerative disease. The program was designed to bring together leading scientists with primary interests in DNA damage signaling with those working in specific related neurodegenerative disease areas as a means for integrating these fields. It was anticipated that this would generate insights into how normal processes of genome maintenance in the brain contribute to the prevention of a wide range of diseases.

  • VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010): Global Approach to Accessibility in Rare Diseases, Orphan Drugs and Neglected Diseases , Thursday, March 18, 2010 - Saturday, March 20, 2010
    Location: Palais Rouge Convention Center, Palermo, Buenos Aires, Argentina
    Description: For the first time, the VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010) was convened in the southern hemisphere in agreement with its aim of globalization of rare diseases research and orphan products development activities.

  • Nutritional Challenges in the High-Risk Infant, Monday, September 14, 2009 - Tuesday, September 15, 2009
    Location: DC Metro Area,
    Description: Evidence was critically evaluated at this workshop. Current gaps in knowledge in this area were identified and research priorities were formulated. The workshop summary will provide NICHD and the scientific community a template to address the scientific and clinical issues related to nutrition and neonatal care.

  • Therapeutic Targets for the Congenital Muscular Dystrophies, Thursday, July 09, 2009 - Saturday, July 11, 2009
    Location: Emory University, Atlanta, Georgia
    Description: The primary goal of the conference is to address, evaluate and achieve consensus on therapeutic targets in the CMDs by bringing together experts ranging from basic science to clinical trial design in rare disorders, as well as representatives from industry, advocacy and funding agencies (NIH and MDA).